Found 89 matching trials
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma PHASE2 This is a phase II, multi-arm, Bayesian adaptive platform trial designed to...
Show More Location
Zhongshan Hospital, Fudan University
Learn More & Join Trial
ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer PHASE1 This is a single-arm, multicenter, phase II study designed to evaluate the ...
Show More Location
Multiple Locations
Learn More & Join Trial
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. PHASE2 This study is a multicenter, prospective, randomized, double-arm, Phase II ...
Show More Location
Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651
Learn More & Join Trial
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. PHASE3 The trial aimed to compare QL1706 combined with induction chemotherapy plus...
Show More Location
Fujian Cancer Hospital
Learn More & Join Trial
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma PHASE2 This is single - arm study to explore the safety and efficacy of iparomlima...
Show More Location
The First Affiliated Hospital of Zhengzhou University
Learn More & Join Trial
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence PHASE2 The purpose of this study is to evaluate the impact of iparomlimab and tuvo...
Show More Location
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer PHASE2 This study is a prospective, single-arm, multicenter exploratory clinical s...
Show More Location
Jiangsu Cancer Hospital
Learn More & Join Trial
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer PHASE2 This study is a single-arm, multicenter, prospective phase II clinical tria...
Show More Location
Jiangsu Cancer Hospital
Learn More & Join Trial
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer PHASE2 Purpose:
To evaluate the efficacy and safety of neoadjuvant treatment with...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC PHASE2 This single-center, single-arm, prospective study plans to enroll patients ...
Show More Location
Jinan Central Hospital
Learn More & Join Trial